Challenges and Solutions in Pathological Diagnosis of Malignant Pleural Mesothelioma
Keywords:
Mesothelioma, Malignant Mesothelioma, Malignant Pleural MesotheliomaAbstract
The tumor known as mesothelioma affects the serosal membranes, which include the testes' tunica vaginalis, peritoneum, pleura, and pericardium. In nations such as Italy, the global incidence of Malignant Mesothelioma (MM) is approximately 1.15 percent out of a hundred thousand people. Malignant Pleural Mesothelioma (MPM), which makes up around 80% of cases, is the most prevalent type of mesothelioma. Although mesothelioma is not prevalent in the general population as a whole, it is linked to exposure to mineral fibers and industrial contaminants, with asbestos being responsible for approximately 80% of instances. In the upcoming years, it is anticipated that the prevalence of MPM will gradually increase globally due to the continued contamination with asbestos in several nations. The tumor invades neighboring structures, causing pleural effusion, discomfort, and dyspnea, and It proceeds from the prefrontal toward the visceral lining following a pattern such as loco-regional of development. Recent research has examined the role of BAP, which was-1 as well as MTAP in the prognosis for the long-term of MPM as well as the diagnosis of cancer in place. There are several aspects of managing preinvasive lesions in mesothelioma that are unknown and up for debate. Three things are necessary to provide sufferers with the treatment they require: the determination of the illness, the current state of the illness, as well as an accurate and thorough examination of the patient.References
Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472-86.
Nakas A, Martin-Ucar AE, Edwards JG, Waller DA. Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery. Eur J Cardiothorac Surg. 2008;33(2):303-6.
Ribak J, Lilis R, Suzuki Y, Penner L, Selikoff IJ. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death. Occup Environ Med. 1988;45(3):182-7.
Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse SF. Previous Version: SEER cancer statistics review, 1975–2010. Natl Cancer Inst. 2013;21:12.
Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Annals of cardiothoracic surgery. 2012;1(4):491.
Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest. 1993;103(4):373S-6S.
Tan E, Warren N, Darnton AJ, Hodgson JT. Projection of mesothelioma mortality in Britain using Bayesian methods. Br J Cancer. 2010;103(3):430-6.
Cai ED, Swetter SM, Sarin KY. Association of multiple primary melanomas with malignancy risk: A population-based analysis of entries from the Surveillance, Epidemiology, and End Results program database during 1973-2014. J Am Acad Dermatol. 2023;88(5):e211-9.
Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 1980;46(12):2736-40.
Geltner C, Errhalt P, Baumgartner B, Ambrosch G, Machan B, Eckmayr J, et al, Austrian Mesothelioma Interest Group (AMIG). Management of malignant pleural mesothelioma–Part 1: Epidemiology, diagnosis, and staging: consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin Wochenschr. 2016;128:611-7
Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:1-7.
Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13(3):153-9.
Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022-5.
Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-72.
Moro J, Sobrero S, Cartia CF, Ceraolo S, Rapanà R, Vaisitti F, et al. Diagnostic and therapeutic challenges of malignant pleural mesothelioma. Diagnostics. 2022;12(12):3009.
Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D'Amico TA, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32.
Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716-24.
Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005 Oct 13;353(15):1591-603.
Sebastien P, Janson X, Gaudichet A, Hirsch A, Bignon J. Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura. IARC Sci Publ. 1980;(30):237-46.
Ault JG, Cole RW, Jensen CG, Jensen LC, Bachert LA, Rieder CL. Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res. 1995;55(4):792-8.
Kamp DW, Israbian VA, Preusen SE, Zhang CX, Weitzman SA. Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am J Physiol-Lung Cell Mol Physiol. 1995;268(3):L471-80.
Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res. 1996;56(23):5334-8.
Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008;9:147-57.
De Assis LV, Isoldi MC. The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms. Tumour Biol. 2014;35:889-901.
Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Occup Environ Med. 1960;17(4):260-71.
Magnani C, Fubini B, Mirabelli D, Bertazzi PA, Bianchi C, Chellini E, et al. Pleural mesothelioma: epidemiological and public health issues. Report from the Second Italian Consensus Conference on Pleural Mesothelioma. Med Lav. 2013;104(3):191-202.
McDonald AD, McDonald JC. Mesothelioma after crocidolite exposure during gas mask manufacture. Environ Res. 1978;17(3):340-6.
Farioli A, Ottone M, Morganti AG, Compagnone G, Romani F, Cammelli S, et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med. 2016;5(5):950-9.
Ngamwong Y, Tangamornsuksan W, Lohitnavy O, Chaiyakunapruk N, Scholfield CN, Reisfeld B, Lohitnavy M. Additive synergism between asbestos and smoking in lung cancer risk: a systematic review and meta-analysis. PLoS One. 2015;10(8):e0135798.
Xu J, Futakuchi M, Shimizu H, Alexander DB, Yanagihara K, et al. Multi-walled carbon nanotubes translocate into the pleural cavity and induce visceral mesothelial proliferation in rats. Cancer Sci. 2012;103(12):2045-50.
Fukushima S, Kasai T, Umeda Y, Ohnishi M, Sasaki T, Matsumoto M. Carcinogenicity of multi-walled carbon nanotubes: challenging issue on hazard assessment. J Occup Health. 2018;60(1):10-30.
Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci. 2010;1203(1):7-14.
Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72(13):3290-301.
Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, et al. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling. Am J Pathol. 2013;183(5):1654-66.
Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, et al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res. 2016;22(12):3087-96.
Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, et al. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer. 2013 Dec;13:1-6.
Moro J, Sobrero S, Cartia CF, Ceraolo S, Rapanà R, Vaisitti F, et al. Diagnostic and therapeutic challenges of malignant pleural mesothelioma. Diagnostics. 2022;12(12):3009.
Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. JNCI: J Natl Cancer Inst. 2018;110(12):1328-41.
Cheung M, Testa JR. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res. 2017;6(3):270.
Louie BH, Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev. 2020;90:102091.
Ismail IH, Davidson R, Gagné JP, Xu ZZ, Poirier GG, Hendzel MJ. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 2014;74(16):4282-94.
Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou Set al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA. 2014;111(1):285-90.
Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem. 2009;284(49):34179-88.
Pan H, Jia R, Zhang L, Xu S, Wu Q, Song X, et al. BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells. Int J Biochem Cell Biol. 2015;60:176-84.
Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J, Sui G, et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol. 2010;30(21):5071-85.
Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, et al. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature. 2017;546(7659):549-53.
Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, et al. Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res. 2016;76(2):206-15.
Haugh AM, Njauw CN, Bubley JA, Verzì AE, Zhang B, Kudalkar E, et al. Genotypic and phenotypic features of BAP1 cancer syndrome: a report of 8 new families and review of cases in the literature. JAMA Dermatol. 2017;153(10):999-1006.
Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76-81.
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410-3.
Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28(8):1043-57.
Salle FG, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, et al. New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center. J Thorac Oncol. 2018;13(8):1189-203.
Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN, et al. Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. Int J Mol Sci. 2021;22(2):690.
Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, Minna JD. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227-31.
Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res. 1997;237(1):7-13.
Komata T, Kanzawa T, Takeuchi H, Germano IM, Schreiber M, Kondo Y, et al. Antitumour effect of cyclin-dependent kinase inhibitors (p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1) on malignant glioma cells. Br J Cancer. 2003;88(8):1277-80.
Li J, Poi MJ, Tsai MD. Regulatory mechanisms of tumor suppressor P16INK4A and their relevance to cancer. Biochemistry. 2011;50(25):5566-82.
Marshall K, Jackson S, Jones J, Holme J, Lyons J, Barrett E, et al. Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre. Lung Cancer. 2020;150:195-200.
Okazaki Y, Misawa N, Akatsuka S, Kohyama N, Sekido Y, Takahashi T, Toyokuni S. Frequent homozygous deletion of Cdkn2a/2b in tremolite-induced malignant mesothelioma in rats. Cancer Sci. 2020;111(4):1180-92.
Nickell Jr LT, Lichtenberger III JP, Khorashadi L, Abbott GF, Carter BW. Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics. 2014;34(6):1692-706.
Giesel FL, Bischoff H, von Tengg-Kobligk H, Weber MA, Zechmann CM, Kauczor HU, et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest. 2006;129(6):1570-6.
Xu LL, Yang Y, Wang Z, Wang XJ, Tong ZH, Shi HZ. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis. BMC Pulm Med. 2018;18:1-9.
Van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254.
Perikleous P, Waller DA. Video-assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases. J Vis Surg. 2017;3.
Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database of Systematic Reviews. 2016(5).
Hassan M, Mercer RM, Maskell NA, Asciak R, McCracken DJ, Bedawi EO, Shaarawy H, El-Ganady A, Psallidas I, Miller RF, Rahman NM. Survival in patients with malignant pleural effusion undergoing talc pleurodesis. Lung Cancer. 2019;137:14-8.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2023;41(12):2125-33.
Gao Y, Kruithof-de Julio M, Peng RW, Dorn P. Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?. Cancers. 2022;14(15):3758.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405-14.
Zhou M, Joshi N, Raj KP, Wakelee H, Neal JW. PD-1/PD-L1 checkpoint inhibitor immunotherapy for malignant pleural mesothelioma: case series and literature review. Clin Lung Cancer. 2021;22(3):e329-35.
Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118-27.
Hylebos M, Van Camp G, Vandeweyer G, Fransen E, Beyens M, Cornelissen R, et al. Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. Oncotarget. 2017;8(69):113673.
Mierzejewski M, Korczynski P, Krenke R, Janssen JP. Chemical pleurodesis–a review of mechanisms involved in pleural space obliteration. Respir Res. 2019;20:1-6.
Kaya SO, Bir F, Atalay H, Onem G, Aytekin FO, Saçar M. Effect of diclofenac on experimental pleurodesis induced by tetracycline in rabbits. J Investig Med. 2005;53(5):267-70.
Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47(4):320-9.
Huynh LK, Hipolito CJ, Ten Dijke P. A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment. Biomolecules. 2019;9(11):743.
Bintcliffe OJ, Lee GY, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. Eur Respir Rev. 2016;25(141):303-16.
Karpathiou G, Péoc’h M, Sundaralingam A, Rahman N, Froudarakis ME. Inflammation of the pleural cavity: a review on pathogenesis, diagnosis and implications in tumor pathophysiology. Cancers. 2022;14(6):1415.
Karpathiou G, Hathroubi S, Patoir A, Tiffet O, Casteillo F, Brun C, et al. Non-specific pleuritis: pathological patterns in benign pleuritis. Pathology. 2019;51(4):405-11.
Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005;129(11):1421-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pakistan Journal of Chest Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
